About Lou Tartaglia
Lou Tartaglia is a Crosslink director and a managing partner and co-founder of Cure Ventures. Crosslink develops cancer medicines that assemble in solid tumors. His biotech career spans more than 30 years across science, product development, and venture investing. In 2016, he ran 5AM Ventures' 4:59 company-building effort and led the formation of Entrada Therapeutics. He then served as Entrada's interim chief executive for its first year. Later, he became a 5AM venture partner and took chief executive roles at startups.
He held two vice president roles at Millennium Pharmaceuticals from 1993 to 2004. From 2004 to 2007, he was Gene Logic's senior vice president and general manager. He joined Third Rock Ventures as a partner in 2007. As of June 2014, he had served on Zafgen's board since October 2007. He holds a doctorate in biochemistry from UC Berkeley and a bachelor's in chemistry from the University at Albany.
Experience
This experience comes from official bios, from Lou Tartaglia's profile and from SEC filings. For roles taken from filings, the years are when the filings name Lou Tartaglia in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Lou Tartaglia works with at each company, as listed on that company's latest Form D.
